The two cut‐offs approach for plasma p‐tau217 in detecting Alzheimer's disease in subjective cognitive decline and mild cognitive impairment
Abstract BACKGROUND The study aimed to explore the applicability of plasma phosphorylated tau (p‐tau)217 in identifying patients with subjective cognitive decline (SCD) and mild cognitive impairment (MCI) carrying Alzheimer's disease (AD) pathology in real‐world settings. METHODS Fifty SCD, 87...
Saved in:
Main Authors: | Giulia Giacomucci, Chiara Crucitti, Assunta Ingannato, Valentina Moschini, Silvia Bagnoli, Federico Emanuele Pozzi, Elisa Marcantelli, Sonia Padiglioni, Carmen Morinelli, Salvatore Mazzeo, Sandro Sorbi, Valentina Berti, Benedetta Nacmias, Valentina Bessi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-04-01
|
Series: | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring |
Subjects: | |
Online Access: | https://doi.org/10.1002/dad2.70116 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Predicting amyloid status in mild cognitive impairment: the role of semantic intrusions combined with plasma biomarkers
by: Yao Lu, et al.
Published: (2025-06-01) -
Beyond language: empathy and emotion recognition deficits in primary progressive aphasias
by: Giulia Giacomucci, et al.
Published: (2025-01-01) -
Exploring the association between mild behavioral impairment and plasma p‐tau217: Implications for early detection of Alzheimer's disease
by: Maryam Ghahremani, et al.
Published: (2025-04-01) -
Development and Validation of the HPLC Method for Quantification of the Innovative Drug DD217, Factor Xa Inhibitor, in Rat Plasma for a Pharmacokinetic Study
by: N. S. Dubovik, et al.
Published: (2022-05-01) -
Analytical and clinical validation of a high accuracy fully automated digital immunoassay for plasma phospho-Tau 217 for clinical use in detecting amyloid pathology
by: David Wilson, et al.
Published: (2025-07-01)